Acer Therapeutics Past Earnings Performance
Past criteria checks 0/6
Acer Therapeutics's earnings have been declining at an average annual rate of -3.5%, while the Pharmaceuticals industry saw earnings growing at 12.9% annually. Revenues have been growing at an average rate of 36.6% per year.
Key information
-3.5%
Earnings growth rate
14.7%
EPS growth rate
Pharmaceuticals Industry Growth | 7.3% |
Revenue growth rate | 36.6% |
Return on equity | n/a |
Net Margin | n/a |
Last Earnings Update | 30 Jun 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Acer Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Jun 23 | 0 | -39 | 11 | 9 |
31 Mar 23 | 0 | -33 | 11 | 11 |
31 Dec 22 | 0 | -26 | 13 | 12 |
30 Sep 22 | 0 | -21 | 13 | 11 |
30 Jun 22 | 0 | -20 | 12 | 10 |
31 Mar 22 | 0 | -20 | 11 | 8 |
31 Dec 21 | 1 | -15 | 11 | 7 |
30 Sep 21 | 1 | -17 | 10 | 8 |
30 Jun 21 | 1 | -20 | 11 | 10 |
31 Mar 21 | 1 | -23 | 12 | 12 |
31 Dec 20 | 0 | -23 | 11 | 12 |
30 Sep 20 | 0 | -22 | 11 | 11 |
30 Jun 20 | 0 | -21 | 10 | 11 |
31 Mar 20 | 0 | -26 | 13 | 12 |
31 Dec 19 | 0 | -29 | 15 | 13 |
30 Sep 19 | 0 | -33 | 16 | 16 |
30 Jun 19 | 0 | -31 | 15 | 15 |
31 Mar 19 | 0 | -25 | 12 | 14 |
31 Dec 18 | 0 | -21 | 9 | 12 |
30 Sep 18 | 0 | -17 | 8 | 9 |
30 Jun 18 | 0 | -17 | 8 | 9 |
31 Mar 18 | 0 | -15 | 7 | 8 |
31 Dec 17 | 0 | -14 | 5 | 9 |
30 Sep 17 | 0 | -12 | 3 | 9 |
30 Jun 17 | 0 | -11 | 2 | 8 |
31 Mar 17 | 0 | -9 | 1 | 8 |
31 Dec 16 | 0 | -7 | 1 | 5 |
Quality Earnings: P6NP is currently unprofitable.
Growing Profit Margin: P6NP is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: P6NP is unprofitable, and losses have increased over the past 5 years at a rate of 3.5% per year.
Accelerating Growth: Unable to compare P6NP's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: P6NP is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (2.8%).
Return on Equity
High ROE: P6NP's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.